PTPN22 and B-cell chronic lymphocytic leukemia: On the one hand, PTPN22 blocks activation of downstream molecules that activate proapoptotic pathways, such as p38MAPK, whereas on the other hand it increases the activity of the AKT kinase, which provides a powerful survival signal to antigen-stimulated CLL cells.